Literature DB >> 17990116

To clot or not to clot: are there predictors of clinically significant thrombus formation in patients with gastroparesis and prolonged IV access?

W Bradley Creel1, Thomas L Abell, Amy Lobrano, Steven R Deitcher, M Dugdale, David Smalley, William D Johnson.   

Abstract

Some patients with gastroparesis (GP) require sustained central intravenous access for hydration, medication and/or nutrition, leaving them at risk for venous thrombosis. We studied a group of 53 patients with gastroparesis for identifiable risk factors of clinically significant thrombosis. Patients requiring prolonged central IV access fell into two groups: those who had clinical incidence of IV catheter-related thrombosis confirmed radiologically (CLOT, n = 14), and those who did not form IV catheter thrombosis (NOCLOT, n = 39). We analyzed and compared clinical symptoms, serum/plasma coagulation studies, and autoimmune antibodies in the CLOT and NOCLOT groups. Patients in the CLOT group had statistically more Scl 70 antibodies than did the NOCLOT group, and another autoantibody, Ku 66, was found in higher titers in the NOCLOT group than the CLOT group. Other autoimmune and coagulation factors were not statistically different between the two groups, although a subgroup of CLOT patients had lower plasma Protein S levels. We conclude that the presence of Scl 70 autoantibodies is associated with increased clotting risk in this group of GP patients, and that the Ku 66 antibody may be associated with decreased risk of thrombosis in patients with GP. These findings, coupled with lower Protein S levels in some CLOT patients, suggests that autoimmune factors may be associated with GP patients who thrombose IV access versus patients who do not.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17990116     DOI: 10.1007/s10620-007-0040-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  3 in total

1.  Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits?

Authors:  T F Cutts; J Luo; W Starkebaum; H Rashed; T L Abell
Journal:  Neurogastroenterol Motil       Date:  2005-02       Impact factor: 3.598

Review 2.  Pathogenetic and diagnostic aspects of siliconosis.

Authors:  D Radford Shanklin; D L Smalley
Journal:  Rev Environ Health       Date:  2002 Apr-Jun       Impact factor: 3.458

Review 3.  Inflammatory neuropathies of the enteric nervous system.

Authors:  Roberto De Giorgio; Stefania Guerrini; Giovanni Barbara; Vincenzo Stanghellini; Fabrizio De Ponti; Roberto Corinaldesi; Peter L Moses; Keith A Sharkey; Gary M Mawe
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

  3 in total
  4 in total

1.  Gastric Electrical Stimulation and Sacral Electrical Stimulation: A Long-Term Follow-Up Study of Dual-Device Treatment.

Authors:  Anubhav Agrawal; Sean Lamar Francis; Nicolette Elizabeth Deveneau; Shaily Jain; Christopher Abrasley; Jason Trippe McNeese; Shivangi T Kothari; Christopher J Lahr; Thomas L Abell
Journal:  Dig Dis Sci       Date:  2015-08-18       Impact factor: 3.199

2.  Gastric dysmotility and low serum vitamin D levels in patients with gastroparesis.

Authors:  A Kedar; Y Nikitina; O R Henry; K B Abell; V Vedanarayanan; M E Griswold; C Subramony; T L Abell
Journal:  Horm Metab Res       Date:  2012-09-06       Impact factor: 2.936

3.  Gastric electrical stimulation for treatment of clinically severe gastroparesis.

Authors:  Naga Venkatesh G Jayanthi; Simon P L Dexter; Abeezar I Sarela
Journal:  J Minim Access Surg       Date:  2013-10       Impact factor: 1.407

4.  Efficacy of Gastric Electrical Stimulation for Gastroparesis: US/European Comparison.

Authors:  Jordan Burlen; Matt Runnels; Minesh Mehta; Stina Andersson; Philippe Ducrotte; Guillaume Gourcerol; Greger Lindberg; Greg Fullarton; Hasse Abrahamsson; Amar Al-Juburi; Chris Lahr; Hani Rashed; Thomas Abell
Journal:  Gastroenterology Res       Date:  2018-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.